 | |
| Clinical data | |
|---|---|
| Trade names | Mustophoran |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.158.792 |
| Chemical and physical data | |
| Formula | C9H19ClN3O5P |
| Molar mass | 315.69 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Fotemustine is anitrosoureaalkylating agent used in the treatment ofmetastaticmelanoma. It is available in Europe but has not been approved by the United States FDA.[1] A study[2] has shown that fotemustine produces improved response rates but does not increase survival (overdacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byadding missing information. |